Clinical trials: Mammary Cancer
Sleep Initiation and Maintenance Disorders, Pain
Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients
Many women with breast cancer who are treated with aromatase inhibitor medications develop difficulty sleeping and fatigue during treatment.
- Trial name
- NCT01921296
- Testing
- Cyclobenzaprine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Lynn Henry
Neoplasms, Breast
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
Evaluate the percentage of clinical objective responses (cOR) in patients with HER2 negative early breast cancer treated with pre operative (neoadjuvant)lapatinib and letrozole
- Trial name
- NCT00422903
- Testing
- lapatinib, letrozole
- Where
- 14 sites in Italy, Spain
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
The open-label Phase Ib portion of this study will evaluate the safety and pharmacokinetics of ipatasertib in combination with palbociclib and fulvestrant to identify a dose of ipatasertib that can be combined with palbociclib…
- Trial name
- IPATunity150 (NCT04060862)
- Testing
- Ipatasertib, Palbociclib, Fulvestrant
- Where
- 20 sites in United States, Australia and 6 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Advanced Breast Cancer
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
- Trial name
- VERITAC-2 (NCT05654623)
- Testing
- ARV-471, Fulvestrant
- Where
- 312 sites in United States, Argentina and 29 more
- Volunteers
- 624 people
- Sponsor
- Pfizer
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
This phase II trial studies how well giving combination chemotherapy and filgrastim together before surgery works in treating patients with human epidermal growth receptor 2 (HER2)-positive breast cancer that can be removed by…
- Conditions
- Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer
- Trial name
- NCT00194779
- Testing
- doxorubicin hydrochloride, cyclophosphamide, paclitaxel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Breast Cancer
Peers Promoting Exercise Adoption and Maintenance Among Cancer Survivors
Exercise adoption enhances well-being and recovery from breast cancer. Researchers trained American Cancer Society volunteers to provide exercise counseling to breast cancer survivors and the survivors increased their exercise in…
- Trial name
- NCT02694640
- Testing
- Reach Plus, Reach Plus Phone, Reach Plus Message
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Ductal Carcinoma in Situ
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
This will be a proof of principle clinical trial to evaluate the use of pasireotide (SOM230) in women with ductal carcinoma in situ (DCIS) of the breast.
- Trial name
- NCT01372618
- Testing
- SOM 230 / Pasireotide
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Uterine Neoplasms, Uterine Cervical Neoplasms
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the…
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
- Trial name
- NCT04579380
- Testing
- tucatinib, trastuzumab, fulvestrant
- Where
- 108 sites in United States, Belgium and 6 more
- Volunteers
- 217 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
This phase IIA trial studies the side effects of ribociclib and aromatase inhibitor and how well they work in treating participants with hormone receptor positive breast cancer that has spread to other places in the body.
- Conditions
- Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT03477396
- Testing
- Aromatase Inhibitor, Laboratory Biomarker Analysis, Pharmacokinetic Study
- Where
- 9 sites in United States
- Volunteers
- 2 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function.
- Trial name
- NCT00464646
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- 36 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- NSABP Foundation Inc
Metastatic Breast Cancer
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer.
- Trial name
- NCT00759642
- Testing
- lapatinib
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
- Trial name
- BELLE-4 (NCT01572727)
- Testing
- Paclitaxel, BKM120
- Where
- 112 sites in United States, Australia and 20 more
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This open-label, multicenter, Phase IIIb study will assess the safety, tolerability and efficacy of a combination therapy of intravenous (IV) pertuzumab (Perjeta), trastuzumab (Herceptin) SC, and taxane chemotherapy (docetaxel…
- Trial name
- SAPPHIRE (NCT02019277)
- Testing
- Docetaxel, Nab-paclitaxel, Paclitaxel
- Where
- 13 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer
This observational study will evaluate the safety and efficacy of triple negative or HR+ patients with HER2-metastatic or locally advanced breast cancer treated with Avastin (bevacizumab) as first line therapy for at least 12…
- Trial name
- NCT01461044
- Where
- 82 sites in France
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Breast
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
Evaluate the activity of Trastuzumab, Lapatinib, and a combination of both agents with chemotherapy in the preoperative (neoadjuvant) treatment of early breast cancer.
- Trial name
- CHERLOB (NCT00429299)
- Testing
- lapatinib, trastuzumab, paclitaxel
- Where
- 17 sites in Germany, Italy and 1 more
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
This early phase I trial studies the side effects of durvalumab and tremelimumab before surgery in treating patients with hormone receptor positive, HER2 negative stage II-III breast cancer.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03132467
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Hepatitis C
Association of Hepatitis C Virus With Breast Cancer
Hepatitis C viral infection is a major health problem in Egypt. The management of breast cancer patients is often complicated by the presence of associated HCV infection.
- Trial name
- NCT04090164
- Where
- Egypt
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Breast Cancer
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
The purpose of this trial is to evaluate time to progression in women with hormone responsive advanced breast cancer treated with a combination of exemestane and fulvestrant.
- Trial name
- NCT00201864
- Testing
- Exemestane, Fulvestrant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes.
- Trial name
- NCT00041119
- Testing
- AC regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 527 sites in United States, South Africa
- Volunteers
- 3,871 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Breast Cancer
Standard Versus Continuous Capecitabine in Advanced Breast Cancer
Capecitabine is active in metastatic breast cancer but the conventional schedule (1250 mg/m2/12 hr 2 weeks on, one week off) produces grade 2 or greater hand and foot syndrome in up to 50% of patients leading to those reductions.
- Trial name
- NCT00418028
- Testing
- Capecitabine
- Where
- Spain
- Volunteers
- 195 people
- Sponsor
- Hospital San Carlos, Madrid
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.